Nedaplatin-based chemotherapy or cisplatin-based chemotherapy combined with intensity-modulated radiotherapy achieve similar efficacy for stage II-IVa nasopharyngeal carcinoma patients

Abstract

This retrospective study compared the efficacy and safety of nedaplatin-based chemoradiotherapy and cisplatin-based chemoradiotherapy in stage II-IVa nasopharyngeal carcinoma (NPC) patients. Patients treated with cisplatin-based or nedaplatin-based chemoradiotherapy between January 2012 and December 2015 were evaluated. Survival was estimated by the Kaplan‒Meier method and compared by the log-rank test. Multivariate analysis was performed using the Cox proportional hazards model. A cohort of 538 NPC patients was enrolled. There were no significant differences in the 5-year overall survival (OS), progression-free survival (PFS), locoregional relapse-free survival (LRRFS), or distant metastasis-free survival (DMFS) between the cisplatin and nedaplatin groups. During the whole treatment course, patients in the cisplatin group had higher incidences of grade 3‒4 vomiting and anorexia, while patients in the nedaplatin group had higher incidences of grade 3‒4 leucopenia and mucositis. In terms of late toxicities, patients in the cisplatin group had a higher incidence of xerostomia. In multivariate analysis, T stage, N stage, and clinical stage were prognostic factors for OS, PFS, and DMFS. In subgroup analyses, nedaplatin-based chemotherapy achieved comparable treatment outcomes in specific populations stratified by age, sex, ECOG PS score and clinical stage. Cisplatin and nedaplatin are effective choices for stage II-IVa NPC patients, with a different spectrum of side effects.

Fabrication of magnetic nanocomposite as responsive drug delivery vehicle for cervical cancer therapy

“…Various drugs are available to treat cervical cancer, such as cisplatin, paclitaxel, and topotecan 4–6 . The first generation of platinum cis ‐diamminedichloroplatinum [II] (DDP) for anti‐tumor chemotherapy (combined with other cancer treatments or with radiotherapy) is cisplatin, which can be used as a first‐line chemotherapeutic drug (in combination with other cancer treatments or with radiotherapy) because of its broad‐spectrum chemotherapeutic properties 7–10 . However, cisplatin remains the only therapeutic option for several tumor types, especially cervical cancer, despite its toxicity and frequent recurrence of resistance phenomena.…”